Phase 1 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older (or teenagers aged 13–17 who weigh at least 40 kg, for certain types of acute lymphoblastic leukemia)
• People who have been diagnosed with certain advanced blood cancers that have come back or stopped responding to treatment, including: chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); certain bone marrow disorders such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or related conditions; certain types of non-Hodgkin lymphoma (NHL); multiple myeloma; or acute lymphoblastic leukemia (ALL) — specific requirements vary by cancer type and group, so confirm details with the trial site
• People with certain blood cancers who have already tried at least one or two prior treatments (the exact number required depends on the cancer type — confirm with the trial site)
• People whose heart is functioning adequately, as measured by a specific heart ultrasound test (confirm with trial site)
• People whose blood, kidney, and liver test results meet the required levels at the time of screening (confirm with trial site)
• People who are able to use at least one reliable form of contraception throughout the study and for 90 days after finishing the study drug — this applies to women who could become pregnant and to men who have not had a sterilisation procedure
• Women who could become pregnant must have a negative pregnancy test before starting the study drug
• Male participants must avoid donating sperm from the start of the study until 90 days after the last dose
• People who are able to understand the study information and sign a consent form before any study procedures begin

Who may not be able to join:

• People who have had a stem cell transplant within the past 60 days, are currently taking immune-suppressing medicines after a transplant, or are experiencing significant graft-versus-host disease
• People who have had another active cancer in the past 12 months that could interfere with the study, with some exceptions (such as stable breast or prostate cancer on hormone therapy, certain treated skin cancers, or cancers treated with the intent to cure — discuss with the trial site)
• People who have received cancer treatments, experimental therapies, or live vaccines within 14 days (or within 5 half-lives of the treatment, whichever is shorter) before the first dose, or who have not sufficiently recovered from side effects of previous treatment
• People who have taken certain medications that affect how the body processes drugs (specific enzyme inhibitors or inducers), or who have consumed grapefruit, Seville oranges, or star fruit within 7 days before starting the study drug
• People who have previously received CAR-T cell therapy may need to wait at least 28 days before joining (confirm with trial site)
• People with serious ongoing medical conditions affecting the kidneys, nervous system, lungs, heart, liver, or immune system that, in the investigator's opinion, could affect their safety or the study results
• People with certain heart rhythm abnormalities, including a prolonged QT interval on a heart tracing, heart failure classified as moderate or severe, a heart attack, stroke, or bleeding in the brain within the past 6 months
• People with a personal history of a specific inherited heart condition (long QT syndrome) or a serious irregular heartbeat called Torsades de Pointes
• People with an uncontrolled active infection (bacterial, fungal, or viral), poorly controlled HIV, or active hepatitis B or C infection
• People who have an unexplained fever above 38.5°C within 7 days before starting the study drug (unless the fever is believed to be caused by the cancer itself — confirm with trial site)
• Women who are pregnant or breastfeeding
• People who are unable to swallow tablets or capsules, or who have conditions affecting how the body absorbs medicines taken by mouth
• People who have active cancer involvement in the brain or spinal cord at the time of screening
• People who have a known allergy to any ingredient in the study drug LP-118
• People currently taking certain medications known to cause a serious heart rhythm problem called Torsades de Pointes (a list of these medications would be reviewed by the trial site)
• People who have had major surgery within 14 days before the first dose of the study drug

Important: Always verify eligibility with the trial site directly before applying.